Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed SARS-CoV-2 infection 5 days prior to randomization~* Initial onset of COVID-19 signs/symptoms within 5 days of randomization~* Fertile participants must agree to use a highly effective method of contraception~Exclusion Criteria:~* Has at least one underlying medical condition associated with an increased risk of developing severe illness from COVID-19~* History of or need for hospitalization for the medical treatment of COVID-19~* Prior diagnosis of SARS-CoV-2 infection (reinfection)~* Known medical history of liver disease~* Receiving dialysis or have known renal impairment~* Known Human Immunodeficiency Virus (HIV) infection with viral load \> 400 copies/ml or taking prohibited medications for HIV treatment~* Suspected or confirmed concurrent active systemic infection other than COVID-19~* Current or expected use of any medications or substances that are highly dependent on Cytochrome P450 3A4 (CYP3A4) for clearance or are strong inducers of CYP3A4~* Has received or is expected to receive monoclonal antibody treatment or convalescent COVID-19 plasma~* Has received any SARS-CoV-2 vaccine within 12 months of screening~* Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19~* Known prior participation in this trial or other trial involving PF-07321332~* Oxygen saturation of \< 92% on room air~* Females who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-07321332/ritonavir (Type: EXPERIMENTAL): Orally administered PF-07321332+ritonavir
- Placebo (Type: PLACEBO_COMPARATOR): Orally administered Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).